• LOGIN
    Login with username and password
Repository logo

BORIS Portal

Bern Open Repository and Information System

  • Publications
  • Theses
  • Research Data
  • Projects
  • Organizations
  • Researchers
  • More
  • Collections
  • Statistics
  • LOGIN
    Login with username and password
Repository logo
Unibern.ch
  1. Home
  2. Publications
  3. Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease

Polysomnographic record and successful management of augmentation in restless legs syndrome/Willis-Ekbom disease

Details
Files
DOI
10.7892/boris.54203
Publisher DOI
10.1016/j.sleep.2014.01.016
PubMed ID
24767724
Abstract
BACKGROUND: Dopamine agonists (DAs) represent the first-line treatment in restless legs syndrome (RLS); however, in the long term, a substantial proportion of patients will develop augmentation, which is a severe drug-related exacerbation of symptoms and the main reason for late DA withdrawal. Polysomnographic features and mechanisms underlining augmentation are unknown. No practice guidelines for management of augmentation are available. METHODS: A clinical case series of 24 consecutive outpatients affected by RLS with clinically significant augmentation during treatment with immediate-release DA was performed. All patients underwent a full-night polysomnographic recording during augmentation. A switchover from immediate-release DAs (l-dopa, pramipexole, ropinirole, rotigotine) to the long-acting, extended-release formula of pramipexole was performed. RESULTS: Fifty percent of patients presented more than 15 periodic limb movements per hour of sleep during augmentation, showing longer sleep latency and shorter total sleep time than subjects without periodic limb movements. In all patients, resolution of augmentation was observed within two to four weeks during which immediate-release dopamine agonists could be completely withdrawn. Treatment efficacy of extended-release pramipexole has persisted, thus far, over a mean follow-up interval of 13 months. CONCLUSIONS: Pramipexole extended release could be an easy, safe, and fast pharmacological option to treat augmentation in patients with restless legs syndrome. As such it warrants further prospective and controlled investigations. This observation supports the hypothesis that the duration of action of the drug plays a key role in the mechanism of augmentation.
Date Issued
2014
Publication Type
Article
Subject(s)
600 Technology > 610 Medicine & health
Language(s)
en
Author(s)
Maestri, Michelangelo
Fulda, Stephany
Ferini-Strambi, Luigi
Zucconi, Marco
Marelli, Sara
Staedler, Claudio
Bassetti, Claudio L.A.  
Universitätsklinik für Neurologie  
Manconi, Mauro
Additional Credits
Universitätsklinik für Neurologie  
Journal
Sleep medicine
Publisher
Elsevier
ISSN
1389-9457
Access(Rights)
restricted
Show full item
BORIS Portal
Bern Open Repository and Information System
Build: 0eaa7c [ 7.08. 11:06]
Explore
  • Projects
  • Funding
  • Publications
  • Research Data
  • Organizations
  • Researchers
  • Audiovisual Material
  • Software & other digital items
  • Events
More
  • About BORIS Portal
  • BORIS Portal & Open Science
  • Send Feedback
  • Cookie settings
  • Service Policy
Follow us on
  • Mastodon
  • YouTube
  • LinkedIn
UniBe logo
Repository logo COAR Notify